



The 65th ASH Annual Meeting Abstracts

ORAL ABSTRACTS

617.ACUTE MYELOID LEUKEMIAS: BIOMARKERS, MOLECULAR MARKERS AND MINIMAL RESIDUAL DISEASE IN DIAGNOSIS AND PROGNOSIS**Clonal Dynamics of *FLT3*-ITD Positive Acute Myeloid Leukemia Patients with Relapsed/Refractory Disease Following Intensive Chemotherapy +/- Midostaurin**

Romane Joudinaud¹, Augustin Boudry², Laurène Fenwarth, MD MSc², Sandrine Geffroy³, Mikaël Salson⁴, Herve Dombret, MD⁵, Céline Berthon, MD⁶, Arnaud Pigneux, MD PhD⁷, Delphine Lebon⁸, Lamy Haddaoui⁹, Raphael Itzykson, MD / PhD¹⁰, Christian Recher, MD PhD¹¹, Audrey Bidet, MD¹², Eric Delabesse, MD PhD¹³, Mathilde Hunault, MD¹⁴, Claude Preudhomme, PharmD, PhD¹⁵, Nicolas Duployez, PharmD, PhD¹⁵, Pierre-Yves Dumas, MDPH¹⁶

¹UMR9020-U1277-CANTHER, Lille, France

²Hematology Laboratory, CHU Lille, Lille, France

³CHU Lille, Lille, FRA

⁴Cristal (UMR CNRS 9189, Univ Lille), Inria, Villeneuve D'Ascq, FRA

⁵Saint Louis Hospital, University of Paris, Paris, France

⁶Hematology Department, CHRU Lille, Lille, France

⁷Hématologie Clinique et Thérapie cellulaire, CHU Bordeaux, Bordeaux, France

⁸Université Picardie Jules Verne, Amiens, FRA

⁹FILO, Paris, France

¹⁰Hematology Department, Saint-Louis Hospital AP-HP Paris France, Paris, France

¹¹Hematology Department, CHU de Toulouse - Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France

¹²Laboratoire d'Hématologie Biologique, CHU Bordeaux, Bordeaux, France

¹³IUCT-Oncopole, Hematology Laboratory, CHU de Toulouse - Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France

¹⁴HOTEL DIEU, ANGERS CEDEX 9, FRA

¹⁵Laboratory of Hematology, Centre Hospitalier Universitaire (CHU) Lille, Lille, France

¹⁶CHU Bordeaux, Service d'Hématologie Clinique et de Thérapie Cellulaire, F-33000 Bordeaux, France;BRIC (BoRdeaux Institute of onCology), UMR1312, INSERM, Univ. Bordeaux, F-33000 Bordeaux, France, Bordeaux, France

Introduction: Despite the wider use of midostaurin (MIDO) in combination with intensive chemotherapy (ICT) as the 1st-line treatment for *FLT3*-mutated acute myeloid leukemia (AML), complete remission (CR) rates are close to 60%, and relapses occur in over 40% of cases, demonstrating the ability of leukemic cells to resist and evade therapy (Stone *et al.*, *NEJM* 2017). Conventional fragment-length analyses of paired diagnosis/relapse samples have shown that *FLT3*-internal tandem duplications (ITDs) are retained in 80% and 50% of cases following ICT alone and MIDO+ICT respectively (Schmalbrock *et al.*, *Blood* 2021). Only limited data are available on the dynamics of *FLT3*-ITDs or other co-mutations in refractory patients (pts). Here, we conducted a retrospective study involving 115 pts with relapsed/refractory AML harboring *FLT3*-ITD at diagnosis.

Materials and methods: Clonal evolution was examined in paired diagnosis/progression blood or bone marrow samples from 115 pts with *FLT3*-ITD+ AML treated with MIDO+ICT (n=33) or ICT alone (n=82). Among them, 21 pts had primary refractory disease (MIDO+ICT, n=8; ICT, n=13) and 94 pts relapsed after achieving CR (MIDO+ICT, n=25; ICT, n=69). *FLT3*-ITDs and co-mutations were screened on genomic DNA by high-throughput sequencing at both timepoints using a custom-designed panel. For accurate annotation and quantification of *FLT3*-ITDs from sequencing data, we used the recently published FiLT3r algorithm (Boudry *et al.*, *BMC Bioinformatics* 2022). For each ITD detected, FiLT3r allelic ratio (AR) was assessed by the ratio between the mutated allele and the wild-type allele.

Results: A total of 226 *FLT3*-ITDs were detected in 115 pts at AML diagnosis, among which 120 (53%) ITDs were found with an AR below 0.05 (Figure 1).

Among pts who achieved CR and experienced relapse (n=94), 48 had multiple *FLT3*-ITDs at diagnosis and 46 had a single *FLT3*-ITD at diagnosis. Overall, we observed a simplification of the *FLT3*-ITD repertoire upon relapse with the persistence of at

least one initial clone in 8/12 [67%] and 24/36 [67%] pts with multiple ITDs receiving MIDO+ICT and ICT alone respectively. In relapsed pts who initially had a single *FLT3*-ITD clone at diagnosis, the addition of MIDO to ICT was associated with a higher rate of *FLT3*-ITD negativity compared to pts receiving ICT alone (6/13 [46%] vs 5/33 [15%]; $P = 0.05$) (Figure 2).

Interestingly, among 21 pts with primary refractory AML, we observed that *FLT3*-ITD mutation status became negative in 5/8 pts (62%) and 2/13 pts (15%) after induction with MIDO+ICT and ICT alone respectively.

We then compared the initial characteristics between retained and lost *FLT3*-ITDs at AML relapse. Lost *FLT3*-ITDs had significantly lower AR than retained clones in both treatment groups. In order to limit the impact of sample dilution on the allele burden, we defined adjusted variant allele frequencies (VAFs) as the VAFs of *FLT3*-ITDs normalized to the VAFs of *NPM1* mutations, whenever applicable. In so doing, we observed that adjusted VAFs of retained *FLT3*-ITDs increased at relapse, regardless of the treatment group (adjusted VAF, diagnosis vs relapse: 0.28 vs 0.86 and 0.88 vs 1.6 in the MIDO+ICT group and ICT alone group; $P = 2.3e-03$ and $P = 2.4e-04$). Importantly, an adjusted VAF higher than 1 was strongly suggestive of a homozygous state of *FLT3*-ITD. Such situation was found to be more prevalent at relapse in both treatment groups. Besides the selection of a dominant *FLT3*-ITD clone, other relapse-related changes including the acquisition of additional mutations will be presented.

Conclusion: Our study of the clonal dynamics of AML with *FLT3*-ITD mutations provides insights into the mechanisms underlying therapy escape. Our data suggest that clonal interference characterized by multiple *FLT3*-ITD clones is associated with a greater ability to select a *FLT3*-ITD-positive clone at relapse in pts receiving MIDO+ICT. Although the addition of MIDO to ICT increases the probability of eradicating a single *FLT3*-ITD clone, *FLT3*-ITD+ relapses remain common following this combination, often with the selection of homozygous *FLT3*-ITD clones and/or the emergence of new mutations. Finally, our data in refractory situation emphasize the need to reassess mutational status at each stage of progression before implementing targeted therapy.

Disclosures Dombret: Jazz Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees, Research Funding; *Pfizer*: Research Funding; *Servier*: Membership on an entity's Board of Directors or advisory committees, Research Funding; *Astellas*: Research Funding; *Incyte*: Membership on an entity's Board of Directors or advisory committees. **Pigneux:** Jazz Pharmaceuticals: Honoraria, Membership on an entity's Board of Directors or advisory committees; *Gilead*: Honoraria; *Abbvie*: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Support for attending meetings; *Servier*: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Support for attending meetings, Research Funding; *Roche*: Research Funding; *BMS*: Membership on an entity's Board of Directors or advisory committees, Research Funding; *Astellas*: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; *Novartis*: Honoraria; *Pfizer*: Membership on an entity's Board of Directors or advisory committees. **Recher:** Jazz Pharmaceuticals: Other: Personal fees, Research Funding; *Novartis*: Other: Personal fees; *Astellas*: Other: Personal fees; *BMS*: Other: Personal fees, Research Funding; *Amgen*: Research Funding; *Abbvie*: Honoraria; *Servier*: Other: Personal fees; *MaatPharma*: Research Funding; *IQVIA*: Research Funding; *Takeda*: Other: Personal fees. **Dumas:** *Novartis*: Honoraria, Other: Research support for institution; *Servier*: Honoraria, Other: Research support for institution; *BMS*: Honoraria, Other: Research support for institution; *Abbvie*: Honoraria; *Astellas*: Honoraria, Other: Research support for institution; *Daiichi-Sankyo*: Honoraria, Other: Research support for institution; *Jazz pharmaceutical*: Honoraria; *Janssen*: Honoraria; *Roche*: Other: Research support for institution.




Figure 1 : Allelic ratios of *FLT3*-ITD clones detected at the time of diagnosis and disease progression (relapse or refractory disease), based on FLT3r algorithm. Each circle represents 1 *FLT3*-ITD clone. N (Diagnosis) = 226. N (Progression) = 118. AR : allelic ratio = number of mutated reads/number of wild-type reads. Threshold = 0.05.




Figure 2 : Patterns of evolution of *FLT3*-ITD clones in relapsed patients according to the number of clones detected at diagnosis and the treatment group. Each square represents 1 patient. Single : unique *FLT3*-ITD clone at diagnosis. Multiple : several *FLT3*-ITD clones at diagnosis. MIDO : midostaurine. ICT : intensive chemotherapy. *FLT3*-ITDpos : *FLT3*-ITD positive. *FLT3*-ITDneg : *FLT3*-ITD negative.

Figure 1

<https://doi.org/10.1182/blood-2023-182018>